Literature DB >> 18059321

Agonist-selective mechanisms of GPCR desensitization.

E Kelly1, C P Bailey, G Henderson.   

Abstract

The widely accepted model of G protein-coupled receptor (GPCR) regulation describes a system where the agonist-activated receptors couple to G proteins to induce a cellular response, and are subsequently phosphorylated by a family of kinases called the G protein-coupled receptor kinases (GRKs). The GRK-phosphorylated receptor then acts as a substrate for the binding of a family of proteins called arrestins, which uncouple the receptor and G protein so desensitizing the agonist-induced response. Other kinases, principally the second messenger-dependent protein kinases, are also known to play a role in the desensitization of many GPCR responses. It is now clear that there are subtle and complex interactions between GRKs and second messenger-dependent protein kinases in the regulation of GPCR function. Functional selectivity describes the ability of agonists to stabilize different active conformations of the same GPCR. With regard to desensitization, distinct agonist-activated conformations of a GPCR could undergo different molecular mechanisms of desensitization. An example of this is the mu opioid receptor (MOPr), where the agonists morphine and [D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin (DAMGO) induce desensitization of the MOPr by different mechanisms, largely protein kinase C (PKC)- or GRK-dependent, respectively. This can be best explained by supposing that these two agonists stabilize distinct conformations of the MOPr, which are nevertheless able to couple to the relevant G-proteins and produce similar responses, yet are sufficiently different to trigger different regulatory processes. There is evidence that other GPCRs also undergo agonist-selective desensitization, but the full therapeutic consequences of this phenomenon await further detailed study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059321      PMCID: PMC2268061          DOI: 10.1038/sj.bjp.0707604

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  87 in total

1.  P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms.

Authors:  Adam R Hardy; Pamela B Conley; Jiansong Luo; Jeffrey L Benovic; Alastair W Poole; Stuart J Mundell
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

Review 2.  Multiple signaling states of G-protein-coupled receptors.

Authors:  Dianne M Perez; Sadashiva S Karnik
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

3.  Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.

Authors:  Elizabeth A Johnson; Sue Oldfield; Ellen Braksator; Ana Gonzalez-Cuello; Daniel Couch; Kellie J Hall; Stuart J Mundell; Chris P Bailey; Eamonn Kelly; Graeme Henderson
Journal:  Mol Pharmacol       Date:  2006-05-08       Impact factor: 4.436

4.  Beta-arrestin mediates desensitization and internalization but does not affect dephosphorylation of the thyrotropin-releasing hormone receptor.

Authors:  Brian W Jones; Patricia M Hinkle
Journal:  J Biol Chem       Date:  2005-09-23       Impact factor: 5.157

5.  Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells.

Authors:  Michelle Trester-Zedlitz; Al Burlingame; Brian Kobilka; Mark von Zastrow
Journal:  Biochemistry       Date:  2005-04-26       Impact factor: 3.162

6.  Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation.

Authors:  Cornelius Krasel; Moritz Bünemann; Kristina Lorenz; Martin J Lohse
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

7.  Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons.

Authors:  Helena Haberstock-Debic; Kyung-Ah Kim; Y Joy Yu; Mark von Zastrow
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

8.  Role of the G protein-coupled receptor kinase site serine cluster in beta2-adrenergic receptor internalization, desensitization, and beta-arrestin translocation.

Authors:  David J Vaughan; Ellen E Millman; Veronica Godines; Jacqueline Friedman; Tuan M Tran; Wenping Dai; Brian J Knoll; Richard B Clark; Robert H Moore
Journal:  J Biol Chem       Date:  2006-01-03       Impact factor: 5.157

9.  The metabotropic glutamate receptor 4 is internalized and desensitized upon protein kinase C activation.

Authors:  Jesper Mosolff Mathiesen; M Teresa Ramirez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

10.  Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes.

Authors:  Xiang Li; Elaine Huston; Martin J Lynch; Miles D Houslay; George S Baillie
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

View more
  148 in total

1.  Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization.

Authors:  Chung Park; Il-Young Hwang; Rajesh K Sinha; Olena Kamenyeva; Michael D Davis; John H Kehrl
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

2.  Cognitive activation by central thalamic stimulation: the yerkes-dodson law revisited.

Authors:  Robert G Mair; Kristen D Onos; Jacqueline R Hembrook
Journal:  Dose Response       Date:  2010-08-20       Impact factor: 2.658

Review 3.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

Review 4.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Surface masking shapes the traffic of the neuropeptide Y Y2 receptor.

Authors:  Michael S Parker; Renu Sah; Steven L Parker
Journal:  Peptides       Date:  2012-06-23       Impact factor: 3.750

6.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 7.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  Shared mechanisms for opioid tolerance and a transition to chronic pain.

Authors:  Elizabeth K Joseph; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

9.  Differential effects of the Gβ5-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release.

Authors:  Darla Karpinsky-Semper; Claude-Henry Volmar; Shaun P Brothers; Vladlen Z Slepak
Journal:  Mol Pharmacol       Date:  2014-02-28       Impact factor: 4.436

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.